{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:19:21Z","timestamp":1778271561588,"version":"3.51.4"},"reference-count":89,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The treatment of adults with Philadelphia chromosome\u2013positive ALL (Ph+ ALL) has evolved significantly over the past 25 years. These changes have been driven largely by the development of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs) such as ponatinib, more accurate risk stratification and monitoring of measurable residual disease (MRD) and, most recently, the frontline use of blinatumomab-based, chemotherapy-free regimens. Although the historical standard of care for newly diagnosed Ph+ ALL was intensive chemotherapy followed by allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in first remission, now most patients can achieve deep and durable remissions\u2014and even cure\u2014with a chemotherapy-free regimen, without the routine need for allo-HSCT. Although the role of allo-HSCT in first remission is diminishing in this new treatment landscape, allo-HSCT remains a reasonable consolidative option for patients with high-risk clinical or molecular features or in treatment settings where frontline blinatumomab and\/or high-sensitivity MRD monitoring are not routinely available. With optimal frontline therapy and close disease monitoring, relapses of Ph+ ALL are increasingly uncommon but still pose a significant clinical challenge. Several new agents, including novel TKIs, bispecific antibodies, and chimeric antigen receptor T-cell therapies, are being evaluated in the relapsed\/refractory setting and may eventually also play a role in frontline treatment of this disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-517464","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:59:36Z","timestamp":1778270376000},"source":"Crossref","is-referenced-by-count":0,"title":["Evolving Paradigms in the Treatment of Philadelphia Chromosome\u2013Positive ALL"],"prefix":"10.1200","volume":"46","author":[{"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[{"name":"Institut d'Investigaci\u00f3 Contra La Leucemia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Abou Dalle","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Goulart","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Ribera","sequence":"additional","affiliation":[{"name":"Institut d'Investigaci\u00f3 Contra La Leucemia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"Centre de Recherche Saint-Antoine INSERM UMRs 938, Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Torrent","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Institute of Oncology Badalona, Hospital Germans Trias i Pujol, Badalona, Spain"},{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2113347"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2405573"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199380"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2922"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.050"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011908"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001495"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30176-5"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26949"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707562"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00319-2"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016272"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529008"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0704"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.118588"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011221"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1287"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-627935"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.228"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29646"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-636548"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023502"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26816"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.67"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-439"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-700153"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114552"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4783"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194508"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6509"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025800"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008216"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01709-y"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015441"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-441"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201217"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02608-4"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30231"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01075"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052746"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351403"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004821"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02674-8"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1574"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00272"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-443"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-442"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0674"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007378"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0329-y"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01496-8"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33529"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01668-0"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.04.018"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-580027"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402636"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016194"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01055-1"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70117"},{"key":"e_1_3_4_64_2","first-page":"1177","article-title":"Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: A campus ALL real-life study","volume":"110","author":"Dragani M","year":"2025","unstructured":"Dragani M, Ansuinelli M, Papayannidis C, et al: Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: A campus ALL real-life study. Haematologica 110:1177-1181, 2025","journal-title":"Haematologica"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35773"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749978"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1159\/000551699"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27022"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.116954"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-6290"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2675"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.3531"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33321"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26238"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19038"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00144-9"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3345"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-647"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406526"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00321"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0095"},{"key":"e_1_3_4_85_2","first-page":"2740","article-title":"Hyper-CVAD plus ponatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"37","author":"Short NJ","year":"2019","unstructured":"Short NJ, Kantarjian H, Ravandi F, et al: Hyper-CVAD plus ponatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Oncol 37:2740-2747, 2019","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-440"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144535"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.260935"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004813"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004607"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-517464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:59:38Z","timestamp":1778270378000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-517464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-517464"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-517464","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e517464"}}